Treatment of mesotheliomatous pleural effusion: Experimental therapy versus thoracoscopic talc poudrage? Pro: Talc poudrage therapy

Journal of Bronchology

Volumn 8, Issue 1, 2001, Pages 54-59

  Aelony, Yossef ^a,b  

^a KAISER PERMANENTE   (United States)

^b Lakeside Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOMODULATING AGENT;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COST OF ILLNESS; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; LUNG RESECTION; MESOTHELIOMA; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; THORACOSCOPY; TREATMENT PLANNING;

EID: 0035175831     PISSN: 10708030     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.lbr.0000011079.00225.df     Document Type: Review

References (46)

1. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma
2. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A Phase II study
3. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
4. Malignant mesothelioma of the pleura: Relation between histological type and clinical behaviour
5. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients
6. Malignant pleural mesothelioma
7. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma
8. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
9. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
10. A proposed new international TNM staging system for malignant pleural mesothelioma
11. Malignant pleural mesothelioma
12. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically
13. Malignant pleural mesothelioma: A case series with prolonged survival averaging 22.4 months after treatment with thoracoscopic talc poudrage pleurodesis
14. Thirty years of mesothelioma in Barrow-in-Furness
15. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography
16. Diagnosing malignant pleural mesothelioma
17. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura
18. Diffuse malignant mesothelioma: A therapeutic dilemma
19. Patterns of failure after trimodality therapy for malignant pleural mesothelioma
20. Aggressive multimodality treatment for malignant pleural mesothelioma
21. Malignant pleural mesothelioma: Report of 19 cases
22. Extrapleural pneumonectomy for diffuse, malignant mesothelioma
23. Chances and results of surgery of malignant mesothelioma of the pleura
24. Trials in malignant mesothelioma: LCSG 851 and 882
25. Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients
26. Multimodality therapy for malignant mesothelioma based on a study of natural history
27. The treatment of malignant mesothelioma of the pleura: Review of a 5-year experience, with special reference to radiotherapy
28. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: A nonrandomized phase II study
29. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
30. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy
31. Cisplatin, mitomycin and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma
32. Clinical efficacy of doxycycline for pleurodesis
33. Iodized talc pleurodesis for the treatment of pleural effusions
34. Treatment of malignant pleural effusion: A method using tube thoracostomy and talc
35. Pleurodesis using talc slurry
36. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion
37. Treatment of mesotheliomatous pleural effusions: Experimental experimental therapy vs. thoracoscopic talc poudrage. Pro: Experimental therapy
38. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions
39. Thoracoscopic talc poudrage pleurodesis for malignant effusions: A review of 360 cases
40. Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions
41. The pathogenesis of malignant and nonmalignant serosal lesions in the body cavities consequent to asbestos exposure
42. Talc induces apoptosis in human malignant mesothelioma cells in vitro
43. Malignant pleural mesothelioma in western Glasgow
44. Diffuse malignant mesothelioma of the pleura: A review of 37 cases
45. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonograpy, and computed tomography in the preoperative staging of non-small-cell lung cancer: A comparison study
46. Effect of volume reduction on lung transplant timing and selection for chronic obstructive pulmonary disease